Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 1998

View Archived Issues

Company Profile: LXR Biotechnology

Cel-Sci's AIDS vaccine trial expanded to include The Netherlands

Novopharm Biotech's NOVOMAb-G2 IgM completes phase I

Integra LifeSciences to begin phase II clinical trials for Peripheral Nerve Regeneration Conduit

ZD-1839, an EGFR-TK inhibitor worthy of further testing

Rhone-Poulenc Rorer and IRORI enter combinatorial chemistry strategic alliance

Enzon allowed patent on its PEG technology

Ribozyme forms new target validation company

Astra and Merck & Co. restructure joint venture

Wyeth-Ayerst and ArQule sign five-year drug discovery collaboration

Hemosol awarded grant for Hemolink development

SB-RA-131012, an MDR-reversing taxane

Montelukast now available in Spain

Lilly expands women's health pipeline

PKC inhibitors for inflammatory/immune disorders developed at Astra

BioChem Pharma describes lactams for thrombotic disorders

Immunosuppressive, antiinflammatory and antitumor rapamycin derivatives

New cell adhesion inhibitors from Chiroscience

Another European market introduction for mizolastine

Czech investigators describe novel CDK inhibitor with potent antitumor activity

IL-2 fusion protein produces remission in late-stage refractory CTCL

Clozapine therapy results in increased leptin levels

YPE-01: a new diarylheptanoid effective against dermal inflammation

AxyS and Roche Bioscience embark on functional genomics collaboration

Nyotran compared to free nystatin and amphotericin B formulations in vitro

Controlled study refutes evidence indicating that garlic lowers lipids

Lilly presents results of first clinical trial evaluating the MDR modulator LY-335979

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...